The type of patients who would benefit from anti-androgen withdrawal therapy: Could it be performed safely for aggressive prostate cancer?

Kazuhiro Matsumoto, Nobuyuki Tanaka, Nozomi Hayakawa, Taisuke Ezaki, Kenjiro Suzuki, Takahiro Maeda, Akiharu Ninomiya, So Nakamura

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This study was designed to detect the factors that were significantly associated with the results of antiandrogen withdrawal (AAWD) therapy, and to examine whether patients with aggressive prostate cancer demonstrating a short prostate-specific antigen (PSA)-doubling time (DT) could benefit from it without even greater exacerbation of the disease. We conducted a retrospective chart review study of 121 patients who received AAWD therapy due to failed combined androgen blockade (CAB) therapy. A reduction in the serum PSA level after AAWD was observed in 35 patients (28.9 %), and a greater than 50 % decrease from the baseline serum PSA level was observed in 16 patients (13.2 %). Shortening of PSA-DT after AAWD was observed in 48 patients (39.7 %). Univariate and multivariate analyses demonstrated that only a long duration of prior anti-androgen treatment was selected as a significant predictor for a good response to AAWD therapy. With respect to exacerbation after AAWD, we found that patients with a short baseline PSA-DT conversely had a low risk of subsequent shortening of PSADT. Using these two factors, we could stratify the patients into four groups, and patients with prior duration of antiandrogen > 18 months and PSA-DT ≤3 months demonstrated the best results with a good response rate (67.9 %) and a low risk for a worsening of the disease (14.3 %). We conclude that AAWD would be effective especially for patients whose cancer progressed rapidly (short PSA-DT) after a long stable period under CAB and should be recommended before embarking on the next therapeutic maneuver.

Original languageEnglish
Article number647
JournalMedical Oncology
Volume30
Issue number3
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Androgen Antagonists
Androgens
Prostatic Neoplasms
Prostate-Specific Antigen
Therapeutics
Serum
Disease Progression
Multivariate Analysis

Keywords

  • Anti-androgen withdrawal therapy
  • Hormonal therapy
  • Prostate cancer
  • PSA-DT

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Medicine(all)

Cite this

The type of patients who would benefit from anti-androgen withdrawal therapy : Could it be performed safely for aggressive prostate cancer? / Matsumoto, Kazuhiro; Tanaka, Nobuyuki; Hayakawa, Nozomi; Ezaki, Taisuke; Suzuki, Kenjiro; Maeda, Takahiro; Ninomiya, Akiharu; Nakamura, So.

In: Medical Oncology, Vol. 30, No. 3, 647, 2013.

Research output: Contribution to journalArticle

Matsumoto, Kazuhiro ; Tanaka, Nobuyuki ; Hayakawa, Nozomi ; Ezaki, Taisuke ; Suzuki, Kenjiro ; Maeda, Takahiro ; Ninomiya, Akiharu ; Nakamura, So. / The type of patients who would benefit from anti-androgen withdrawal therapy : Could it be performed safely for aggressive prostate cancer?. In: Medical Oncology. 2013 ; Vol. 30, No. 3.
@article{30427fe44e8d4b30b67fe0160787774c,
title = "The type of patients who would benefit from anti-androgen withdrawal therapy: Could it be performed safely for aggressive prostate cancer?",
abstract = "This study was designed to detect the factors that were significantly associated with the results of antiandrogen withdrawal (AAWD) therapy, and to examine whether patients with aggressive prostate cancer demonstrating a short prostate-specific antigen (PSA)-doubling time (DT) could benefit from it without even greater exacerbation of the disease. We conducted a retrospective chart review study of 121 patients who received AAWD therapy due to failed combined androgen blockade (CAB) therapy. A reduction in the serum PSA level after AAWD was observed in 35 patients (28.9 {\%}), and a greater than 50 {\%} decrease from the baseline serum PSA level was observed in 16 patients (13.2 {\%}). Shortening of PSA-DT after AAWD was observed in 48 patients (39.7 {\%}). Univariate and multivariate analyses demonstrated that only a long duration of prior anti-androgen treatment was selected as a significant predictor for a good response to AAWD therapy. With respect to exacerbation after AAWD, we found that patients with a short baseline PSA-DT conversely had a low risk of subsequent shortening of PSADT. Using these two factors, we could stratify the patients into four groups, and patients with prior duration of antiandrogen > 18 months and PSA-DT ≤3 months demonstrated the best results with a good response rate (67.9 {\%}) and a low risk for a worsening of the disease (14.3 {\%}). We conclude that AAWD would be effective especially for patients whose cancer progressed rapidly (short PSA-DT) after a long stable period under CAB and should be recommended before embarking on the next therapeutic maneuver.",
keywords = "Anti-androgen withdrawal therapy, Hormonal therapy, Prostate cancer, PSA-DT",
author = "Kazuhiro Matsumoto and Nobuyuki Tanaka and Nozomi Hayakawa and Taisuke Ezaki and Kenjiro Suzuki and Takahiro Maeda and Akiharu Ninomiya and So Nakamura",
year = "2013",
doi = "10.1007/s12032-013-0647-z",
language = "English",
volume = "30",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - The type of patients who would benefit from anti-androgen withdrawal therapy

T2 - Could it be performed safely for aggressive prostate cancer?

AU - Matsumoto, Kazuhiro

AU - Tanaka, Nobuyuki

AU - Hayakawa, Nozomi

AU - Ezaki, Taisuke

AU - Suzuki, Kenjiro

AU - Maeda, Takahiro

AU - Ninomiya, Akiharu

AU - Nakamura, So

PY - 2013

Y1 - 2013

N2 - This study was designed to detect the factors that were significantly associated with the results of antiandrogen withdrawal (AAWD) therapy, and to examine whether patients with aggressive prostate cancer demonstrating a short prostate-specific antigen (PSA)-doubling time (DT) could benefit from it without even greater exacerbation of the disease. We conducted a retrospective chart review study of 121 patients who received AAWD therapy due to failed combined androgen blockade (CAB) therapy. A reduction in the serum PSA level after AAWD was observed in 35 patients (28.9 %), and a greater than 50 % decrease from the baseline serum PSA level was observed in 16 patients (13.2 %). Shortening of PSA-DT after AAWD was observed in 48 patients (39.7 %). Univariate and multivariate analyses demonstrated that only a long duration of prior anti-androgen treatment was selected as a significant predictor for a good response to AAWD therapy. With respect to exacerbation after AAWD, we found that patients with a short baseline PSA-DT conversely had a low risk of subsequent shortening of PSADT. Using these two factors, we could stratify the patients into four groups, and patients with prior duration of antiandrogen > 18 months and PSA-DT ≤3 months demonstrated the best results with a good response rate (67.9 %) and a low risk for a worsening of the disease (14.3 %). We conclude that AAWD would be effective especially for patients whose cancer progressed rapidly (short PSA-DT) after a long stable period under CAB and should be recommended before embarking on the next therapeutic maneuver.

AB - This study was designed to detect the factors that were significantly associated with the results of antiandrogen withdrawal (AAWD) therapy, and to examine whether patients with aggressive prostate cancer demonstrating a short prostate-specific antigen (PSA)-doubling time (DT) could benefit from it without even greater exacerbation of the disease. We conducted a retrospective chart review study of 121 patients who received AAWD therapy due to failed combined androgen blockade (CAB) therapy. A reduction in the serum PSA level after AAWD was observed in 35 patients (28.9 %), and a greater than 50 % decrease from the baseline serum PSA level was observed in 16 patients (13.2 %). Shortening of PSA-DT after AAWD was observed in 48 patients (39.7 %). Univariate and multivariate analyses demonstrated that only a long duration of prior anti-androgen treatment was selected as a significant predictor for a good response to AAWD therapy. With respect to exacerbation after AAWD, we found that patients with a short baseline PSA-DT conversely had a low risk of subsequent shortening of PSADT. Using these two factors, we could stratify the patients into four groups, and patients with prior duration of antiandrogen > 18 months and PSA-DT ≤3 months demonstrated the best results with a good response rate (67.9 %) and a low risk for a worsening of the disease (14.3 %). We conclude that AAWD would be effective especially for patients whose cancer progressed rapidly (short PSA-DT) after a long stable period under CAB and should be recommended before embarking on the next therapeutic maneuver.

KW - Anti-androgen withdrawal therapy

KW - Hormonal therapy

KW - Prostate cancer

KW - PSA-DT

UR - http://www.scopus.com/inward/record.url?scp=84892382233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892382233&partnerID=8YFLogxK

U2 - 10.1007/s12032-013-0647-z

DO - 10.1007/s12032-013-0647-z

M3 - Article

C2 - 23797774

AN - SCOPUS:84892382233

VL - 30

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 3

M1 - 647

ER -